Home › Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)
 

Keywords :   


Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)

2013-12-30 06:54:32| drugdiscoveryonline News Articles

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, recently announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin (RX-5902)

Tags: method treatment solid patent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »